The ARTNet research centers will adhere to the central goal, which is to balance basic, pre-clinical, and translational research using an iterative team science structure that will enable hypothesis testing on the biological basis of resistance in clinically relevant model systems. The centers will work to provide evidence along the shared tumor-tumor microenvironment (TME) continuum to inform new strategies that can be better translated into future clinical trials.

ARTNet research centers are focused on addressing significant challenges in acquired resistance and disease recurrence. Collectively, the network represents a range of treatment modalities (e.g., chemotherapy, radiation, targeted agents, immunotherapies, combined modalities) and cancer types in pursuit of addressing compelling questions and significant barriers in acquired therapy resistance research.